In the vast and varied panorama of diseases of the nervous system, rare or low-prevalence neurological diseases are of particular interest.
These are all those pathological conditions affecting the central nervous system that meet the minimum criteria to be classified as rare diseases (in the EU, all diseases with a prevalence of less than 5 cases per 10,000 people). Even if they do not have the absolute requisites to satisfy this stringent definition, diseases that are rather infrequent in relation to the most common neurological morbidities are also included in this category.
This wide and differentiated group of conditions comprises, for example, rare epileptic forms such as Lennox-Gastaut’s syndrome, progressive myoclonic epilepsy and West’s syndrome as well as various other pathologies that, for one reason or another, affect the nervous system.
In the past, scientific and clinical research has often neglected the in-depth study of effective therapeutic approaches to these serious and debilitating diseases, but more recently they have seen a revival of interest, sometimes accompanied by the discovery of appropriate able to change the course of clinical history.
PIAM, which has always been involved in the world of neurology, has also chosen to commit itself to tackling these pathologies, which represent a serious problem that is still partially unsolved in the panorama of contemporary medicine.